Engineered protease-resistant antibodies with selectable cell-killing functions.


Molecularly engineered antibodies with fit-for-purpose properties will differentiate next generation antibody therapeutics from traditional IgG1 scaffolds. One requirement for engineering the most appropriate properties for a particular therapeutic area is an understanding of the intricacies of the target microenvironment in which the antibody is expected… (More)
DOI: 10.1074/jbc.M113.486142


8 Figures and Tables